High-grade Glioma Market

Highly Malignant or High-Grade Gliomas (HGG) are tumours of the central nervous system (CNS). They are solid tumours arising from transformed cells called astrocytes of the brain and/or the spinal cord. Since they directly originate from the CNS, they are also called primary CNS tumours, thereby differentiating them from malignant tumours of other organs that have spread (metastasised) to the CNS.

High-grade Glioma Market Key Facts
According to The Royal Marsden, NHS Foundation Trust, HGG are the most common type of adult brain tumour and although they look the same under the microscope, they may be different biologically. Less than 30 children a year develop high grade glioma in the UK. This is about 8% of all childhood brain and spinal cord tumours.
As per a study conducted by Yiallouros et al. titled “High-Grade Gliomas (HGG) - Brief Information”, HGGs account for approximately 15-20 % of CNS tumours in children and adolescents. Each year, about 60-80 children and adolescents younger than 15 years of age are newly diagnosed with a HGG. This corresponds to an incidence rate of 5-10 new diagnoses per 1.000.000 children per year.

High-grade Glioma Market
The High-grade Glioma market analysis report helps to build the detailed comprehension of the historic, current and forecasted High-grade Glioma market trends by evaluating the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of High-grade Glioma market Size and Share analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.

For more information on High-grade Glioma Market, visit:
https://www.delveinsight.com/report-store/high-grade-glioma-market